Generics for Xarelto (Rivaroxaban) are rapidly increasing their prescription performance. In the first half of last year, prescription sales of 8 billion won were recorded, more than doubling in one year. On the other hand, the original product's prescription performance decreased by half during the same period.

Generics for Xarelto, 3.9 billion → 8 billion won growth in one year, original cut in half

According to UBIST, a pharmaceutical market research institute on the 1st, the number of outpatient prescriptions for rivaroxaban in Korea in the first half of last year was 23.8 billion won, down 29% from 33.5 billion won in the same period last year. During this period, Xarelto, the or